3:48 PM · 19 December 2023

CureVac loses 34% as German court quashes company's patent

CureVac (CVAC.US) loses more than 30% today after a German court quashed a company's patent. As Reuters analysis reports, the patent in question is one of several intellectual property titles that CureVac claims were infringed in ongoing legal proceedings. The patent was also the basis of a patent violation lawsuit by CureVac against its market rival and mRNA vaccines producer, BioNTech (BNTX.US), in a blow to CureVac's claims for a share in billions of euros in COVID-19 vaccine revenues. As presiding judge in Germany's patent court, said in his ruling after a hearing, the patent is now invalid for the Germany territory. Biontech's shares are up 2% today. CureVac'smRNA-based COVID-19 vaccine didn't bring any significant cash from sales. At the same time, BioNTech / Pfizer collaboration made more than $40 billion in combined vaccines sales in 2021 and 2022. 

Source: xStation5

25 September 2026, 6:54 PM

Daily summary: Nasdaq gains despite rising bond yields 📈 Oil below $100

25 September 2026, 5:56 PM

Defense stocks after the correction 🚩 Opportunity or trap?

25 September 2026, 2:57 PM

US Open: Wall Street moves higher as oil slides 🗽 Synopsys shares jump on HSBC upgrade

25 September 2026, 2:55 PM

Microsoft is turning Copilot into a revenue Engine for AI

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits